High Cure Rates for HCV Patients Undergoing Liver Transplant with New DAAs

AGA Reading Room 03.30.2017
High Cure Rates for HCV Patients Undergoing Liver Transplant with New DAAs
Indications that post-transplant treatment should start sooner rather than later
by Liz Highleyman
Contributing Writer, MedPage Today

For hepatitis C patients who receive liver transplants, a population that is challenging to treat with interferon-based therapy, treatment with new direct-acting antivirals (DAAs) leads to high cure rates.

The choice of which DAA to use depends on the hepatitis C virus (HCV) genotype and the severity of liver damage. Outcomes are better in people who have not yet developed severe damage in the new liver, suggesting that post-transplant treatment should be started sooner rather than later.
Continue reading....